Because PNPLA8 is activated by SREBP-2, our results also provide a mechanism for he beneficial pharmacologic targeting of SREBP-2 by statins in patients with NAFLD. The gene discussed is SREBF2; the disease is metabolic dysfunction-associated steatotic liver disease.